cyc 202 has been researched along with isoxazoles in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 8,633 | 900 | 3,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cory, AH; Cory, JG; Edwards, CC; Hall, JG | 1 |
1 other study(ies) available for cyc 202 and isoxazoles
| Article | Year |
|---|---|
Inhibitors of diverse metabolic steps cause increased apoptosis in deoxyadenosine-resistant mouse leukemia L1210 cells that lack p53 expression: convergence at caspase-3 activation.
Topics: Androstadienes; Animals; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyrates; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Coloring Agents; Deoxyadenosines; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Genistein; Isoxazoles; Leflunomide; Mice; Models, Biological; Purines; RNA, Messenger; Roscovitine; Sesquiterpenes; Time Factors; Tumor Suppressor Protein p53; Wortmannin | 2003 |